Tyra Biosciences (NASDAQ:TYRA) Coverage Initiated at UBS Group

UBS Group initiated coverage on shares of Tyra Biosciences (NASDAQ:TYRA) in a research report sent to investors on Tuesday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $28.00 price target on the stock.

TYRA has been the subject of several other research reports. HC Wainwright lowered their target price on shares of Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating for the company in a report on Monday, November 11th. Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and increased their price target for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Wedbush reiterated an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a research report on Friday, October 25th. Finally, Oppenheimer boosted their target price on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research note on Thursday, September 19th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $30.50.

Tyra Biosciences Stock Up 0.1 %

NASDAQ TYRA opened at $15.97 on Tuesday. Tyra Biosciences has a twelve month low of $11.32 and a twelve month high of $29.60. The business has a 50-day moving average price of $15.48 and a 200-day moving average price of $19.22. The firm has a market cap of $808.13 million, a price-to-earnings ratio of -9.92 and a beta of 1.04.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). Research analysts expect that Tyra Biosciences will post -1.57 EPS for the current fiscal year.

Insider Buying and Selling at Tyra Biosciences

In other news, Director Nina S. Kjellson sold 27,493 shares of Tyra Biosciences stock in a transaction on Friday, November 1st. The stock was sold at an average price of $16.56, for a total transaction of $455,284.08. Following the transaction, the director now owns 458,506 shares in the company, valued at $7,592,859.36. The trade was a 5.66 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Todd Harris sold 19,084 shares of the stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $27.90, for a total transaction of $532,443.60. Following the completion of the sale, the chief executive officer now directly owns 1,355,927 shares of the company’s stock, valued at approximately $37,830,363.30. This trade represents a 1.39 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 84,160 shares of company stock worth $1,827,047. Insiders own 15.40% of the company’s stock.

Institutional Investors Weigh In On Tyra Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TYRA. American Century Companies Inc. lifted its stake in Tyra Biosciences by 582.9% during the second quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock worth $2,723,000 after purchasing an additional 145,346 shares in the last quarter. Perceptive Advisors LLC boosted its stake in shares of Tyra Biosciences by 50.5% in the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after purchasing an additional 338,208 shares during the period. Janus Henderson Group PLC purchased a new stake in Tyra Biosciences during the 3rd quarter worth approximately $24,994,000. Ensign Peak Advisors Inc acquired a new position in shares of Tyra Biosciences in the second quarter worth $3,047,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Tyra Biosciences during the third quarter worth $593,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.